Apellis Pharmaceuticals Stock News

Apellis Pharmaceuticals Inc (NASDAQ: APLS ) shares are trading higher by 8.6% at $43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phase 3 Derby and Oaks studies for geographic atrophy. Apellis Pharmaceuticals says, at month 18, Pegcetacoplan continued to demonstrate a favorable safety profile, consistent with safety at 12 months and longer-term exposure to intravitreal injections. The … Full story available on Benzinga.com

Apellis Pharmaceuticals Inc (NASDAQ: APLS) announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan continued to reduce geographic atrophy (GA

Commercial-stage biotech Apellis Pharmaceuticals (APLS) is trading ~5% higher in the pre-market Wednesday after announcing long-term data from two late-stage trials for pegcetacoplan,…

WALTHAM, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced longer-term data from th

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher by 8.6% at $43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phas

Shares of Apellis Pharmaceuticals Inc. APLS, +1.55% gained 6.1% in premarket trading on Wednesday after the company shared longer-term clinical data demonstrating that intravitreal pegcetacoplan reduc

Over the past 3 months, 4 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with underst

Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0

In the last trading session, 1.42 million Apellis Pharmaceuticals Inc. (NASDAQ:APLS) shares changed hands as the company’s beta touched 1.52. With the company’s per share price at $44.74 changed hands at $2.21 or 5.20% during last session, the market valuation stood at $4.43B. APLS’s last price was a discount, traded about -63.16% off its 52-week … Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Stock Could Make A -154.81% Loss Read More »

Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.

Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.

Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q4 2021 Results - Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -21.97% and 607.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead fo